by Jen Hodson | Sep 10, 2020 | Press Release
SAN DIEGO, Calif., September 10, 2020 – Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of...
by Jen Hodson | May 1, 2019 | Press Release
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO–May 1, 2019– Brink Biologics, Inc., a NantKwest,...
by Jen Hodson | Apr 1, 2019 | Press Release
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019CULVER CITY, CA – April 1, 2019 – NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced...
